Patrick J. Heron - 05 Jun 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 21:21:32 UTC
Prior SEC filing: 05 Jun 2026
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, Attorney-in-Fact for Patrick J. Heron

Key filing fact

Patrick J. Heron filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 09 Jun 2026.

Key facts

This page summarizes Patrick J. Heron's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 21:21.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001365617 Primary reporting owner

Heron Patrick J

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, Attorney-in-Fact for Patrick J. Heron
Signature date: 09 Jun 2026

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value
Shares: +5,778
Change %: +22%
Price: $0.000000^*
Shares after: 32,213
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24,802
Date: 05 Jun 2026
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,785,284
Date: 05 Jun 2026
Ownership: By Frazier Life Sciences VIII, L.P.
Footnotes: F3

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7
Date: 05 Jun 2026
Ownership: By FHM Life Sciences VIII, L.L.C.
Footnotes: F4

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 23,688
Date: 05 Jun 2026
Ownership: By The Heron Living Trust 11/30/2004
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +16,667
Change %
Price: $0.000000^*
Shares after: 16,667
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,667
Exercise price: $21.23
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2025, maintained by the Company.

Footnote F2

The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Footnote F3

The shares reported herein are held of record by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Footnote F4

The shares reported herein are held of record by FHM Life Sciences VIII, L.L.C. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Footnote F5

The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Footnote F6

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.